



**China Blood Product Industry Report,
2020-2026**

Jan.2020

STUDY GOAL AND OBJECTIVES

This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

REPORT OBJECTIVES

- ◆ To establish a comprehensive, factual, annually updated and cost-effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.
- ◆ To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
- ◆ To complement the organizations' internal competitor information gathering efforts with strategic analysis, data interpretation and insight.
- ◆ To suggest for concerned investors in line with the current development of this industry as well as the development tendency.
- ◆ To help company to succeed in a competitive market, and

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

INFORMATION SOURCES

The primary information sources include Company Reports, and National Bureau of Statistics of China etc.

Abstract

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimbursement from the national medical insurance system. In 2019, the lot release of blood products in China increased further and reached 89.89 million bottles with a year-on-year surge of 21.6%.

Elaborately, the lot release of human albumin rose 17.2% on an annualized basis, making up 58.9%; that of human rabies immunoglobulin soared by 42.9% and accounted for 13.6%; that of human immunoglobulin (pH4) for intravenous injection as a percentage of 13% in the total showed a year-on-year increase of 14.1%; and that of human tetanus immunoglobulin surged by 76.7% and occupied 6.9%.

Other products had small shares, such as human fibrinogen, three kinds of special immunoglobulin, human prothrombin complex, human coagulation factor VIII, particularly coagulation factor category as the lifesaving drug to the victims of hemophilia are often in short supply largely because of the shortage of plasma raw materials domestically as well as the low utilization of plasma.

As the prices of blood products are decontrolled and new plasma stations accelerate to be constructed in recent years, plasma collection in China has been growing year after year, reaching 8,600 tons or more in 2018 with a year-on-year increase of 7.5%. Of all, Beijing Tiantan Biological Products Co., Ltd in possession of 57 plasma stations ranked first by plasma collection up to 1,568.7 tons, a 16.5% share of the total, and its production efficiency gets improved significantly after an asset restructuring.

Number of Plasma Stations and Plasma Collection of Major Chinese Blood Product Enterprises, as of Dec.2019

	Number of Plasma Stations	2016	2017	2018	2019H1
Beijing Tiantan Biological Products	57 (51 ones in operation)	683 tons	862.17 tons	1,568.07 tons	802.55 tons
Shanghai RAAS Blood Products	41	Nearly 900 tons	Over 1,000 tons	1,180 tons	
China Biologic Products Holdings, Inc.	27 (the wholly funded subsidiary Guizhou Taibang with 8 ones, the shareholding subsidiary Shandong Taibang with 16 ones, and the joint-stock company Xi'an Huitian with 3 ones)	About 860 tons	--	--	--
Hualan Biological Engineering	26 (4 in Guangxi, 1 in Guizhou, 16 in Chongqing, 5 in Henan)	1000 tons or more	Nearly 1,100 tons		
Southern Shuanglin Bio-Pharmacy	13	Production-use plasma volume 303.9 tons	Production-use plasma volume 322.8 tons	Nearly 400 tons	
Sichuan Yuanda Shuyang Pharmaceutical	15	--	--		
Jiangxi Boya Bio-Pharmaceutical	12	About 250 tons	Plasma collection about 320 tons	350 tons	
Beijing Bohui Innovation Technology	13 (Hebei Daan Pharmaceutical Co., Ltd with 6 ones, Guangdong Wellen Biological Pharmaceutical Co., Ltd with 7 ones)	--	180 tons	235 tons	
Shanxi Kangbao Biological Product	10	--	--		
Weiguang Biological Products	8	319.52 tons	Over 340 tons	360 tons	
Nanyue Biopharming	7	--	--		
Wuhan ZhongyuanRuide Biological Products	4	--	--		
Green Cross China	4	--	--		

Note: Beijing Tiantan Biological Products Co., Ltd's plasma collection in 2018 included those from Lanzhou Lansheng Blood Products, Shanghai Blood Products, Wuhan Bloods Products and Guizhou Blood Products.

Source: ResearchInChina

Copyright 2012ResearchInChina

There are now about thirty blood product enterprises in China, but they are small-sized without rich product portfolios. The industry desires to be concentrated. It is starting from 2008 that the leading players staged mergers and acquisitions and have been developing apace mainly through M&A whilst independently building plasma stations. Meanwhile, some influential companies have turned their attention to overseas resources and good mode and have been actively exploring overseas markets through acquisitions and introducing state-of-the-art technologies from abroad. Undoubtedly, the Chinese market of blood products will get ever concentrated.

What's more, leading competitors beef up research and development of new products successively and strive to improve comprehensive utilization of plasma. A case in point is the coagulation factorVIII. Only a few Chinese companies such as China Biologic Products Holdings, Inc., Hualan Biological Engineering Co., Ltd., Shanghai RAAS Blood Products Co., Ltd and Green Cross China are competent to produce the coagulation factorVIII, but the peers including Jiangxi Boya Bio-Pharmaceutical Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Southern Shuanglin Bio-Pharmacy Co., Ltd. (formerly known as Zhenxing Biopharmaceutical & Chemical Co., Ltd.), Wuhan ZhongyuanRuide Biological Products Co., Ltd., Beijing Bohui Innovation Technology Co., Ltd., Shenzhen Weiguang Biological Products Co., Ltd and Nanyue Biopharming Co., Ltd. are chasing hard and sparing no efforts in the development of the coagulation factorVIII.

China Blood Product Industry Report, 2020-2026 covers the following:

- ◆ Blood product market (policy, status quo, market structure, supply & demand, market size and competitive pattern);
- ◆ Blood product market segments (development, bidding price, competitive landscape);
- ◆ 13 blood product companies (operation, revenue structure, gross margin and blood product business, etc.);
- ◆ Summary and forecast.

1. Blood Products

- 1.1 Definition
- 1.2 Classification
- 1.3 Recombinant Blood Products
- 1.4 Industry Chain
- 1.5 Features

2. China Blood Product Market

- 2.1 Policies
- 2.2 Status Quo
- 2.3 Market Structure
- 2.4 Market Supply and Demand
 - 2.4.1 Supply
 - 2.4.2 Demand
- 2.5 Market Size
- 2.6 Competition Pattern

3. China Blood Product Market Segments

- 3.1 Human Albumin
 - 3.1.1 Development Status
 - 3.1.2 Bid Price
 - 3.1.3 Market Structure
 - 3.1.4 Competition Pattern
 - 3.1.5 Prospects

3.2 Human Immunoglobulin (pH4) for Intravenous Injection

- 3.2.1 Development Status
- 3.2.2 Bid Price
- 3.2.3 Competition Pattern
- 3.2.4 Prospects

3.3 Coagulation Factor VIII

- 3.3.1 Development Status
- 3.3.2 Bid Price
- 3.3.3 Competition Pattern
- 3.3.4 Prospects

3.4 Hepatitis B Immunoglobulin

- 3.4.1 Development Status
- 3.4.2 Bid Price
- 3.4.3 Competition Pattern

3.5 Human Immunoglobulin

- 3.5.1 Development Status
- 3.5.2 Bid Price
- 3.5.3 Competition Pattern

3.6 Human Prothrombin Complex

- 3.6.1 Development Status
- 3.6.2 Bid Price
- 3.6.3 Competition Pattern

3.7 Tetanus Immunoglobulin

- 3.7.1 Development Status

3.7.2 Bid Price

3.7.3 Competition Pattern

3.8 Human Rabies Immunoglobulin

3.8.1 Development Status

3.8.2 Bid Price

3.8.3 Competition Pattern

4. Major Enterprises

4.1 China Biologic Products (CBPO)

4.1.1 Profile

4.1.2 Operation

4.1.3 Revenue Structure

4.1.4 Gross Margin

4.1.5 R&D Investment

4.1.6 Blood Products Business

4.1.7 Guizhou Taibang Biological Products Co., Ltd.

4.1.8 Shandong Taibang Biological Products Co., Ltd.

4.1.9 Xi'an Huitian Blood Products Co., Ltd.

4.2 Hualan Biological Engineering Co., Ltd.

4.2.1 Profile

4.2.2 Operation

4.2.3 Revenue Structure

4.2.4 Gross Margin

4.2.5 R&D Investment

4.2.6 Blood Products Business

4.2.7 Development Strategy

4.3 Shanghai RAAS Blood Products Co., Ltd.

4.3.1 Profile

4.3.2 Operation

4.3.3 Revenue Structure

4.3.4 Gross Margin

4.3.5 R&D Investment

4.3.6 Blood Products Business

4.3.7 Development Strategy

4.4 Beijing Tiantan Biological Products

4.4.1 Profile

4.4.2 Operation

4.4.3 Revenue Structure

4.4.4 Gross Margin

4.4.5 R&D Investment

4.4.6 Blood Products Business

4.4.7 Chengdu Rongsheng

4.5 Guangdong Shuanglin Bio-Pharmacy

4.5.1 Profile

4.5.2 Operation

4.5.3 Gross Margin

4.5.4 R&D Investment

4.5.5 Blood Products Business

4.5.6 Development Strategy

4.6 Jiangxi Boya Bio-Pharmaceutical

4.6.1 Profile

4.6.2 Operation

4.6.3 Revenue Structure

4.6.4 Gross Margin

4.6.5 R&D Investment

4.6.6 Blood Products Business

4.6.7 Development Strategy

4.7 Weiguang Biological Products

4.7.1 Profile

4.7.2 Operation

4.7.3 Revenue Structure

4.7.4 Gross Margin

4.7.5 R&D Investment

4.7.6 Blood Products Business

4.7.7 Development Strategy

4.8 Beijing Bohui Innovation Technology

4.8.1 Profile

4.8.2 Operation

4.8.3 Revenue Structure

4.8.4 Gross Margin

4.8.5 R&D Investment

4.8.6 Blood Products Business

4.8.7 Development Strategy

4.9 Wuhan ZhongyuanRuide Biological Products Co., Ltd.

4.9.1 Profile

4.9.2 Operation

4.9.3 Blood Products Business

4.10 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

4.11 Shanxi Kangbao Biological Product Co., Ltd.

4.12 Green Cross China

4.13 Nanyue Biopharming Corporation Ltd.

5. Summary and Forecast

5.1 Summary

5.2 Development Trend

5.2.1 The Industry Continues to Boom

5.2.2 Industry Integration Speeds Up, Concentration Rises Further

5.2.3 Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry

5.2.4 Plasma Volume Increases Progressively

5.2.5 Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness, Comprehensive Utilization of Blood Plasma Gets a Further Rise

5.2.6 Downstream Demand Stimulates the Development of the Industry

5.2.7 Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Development of the Industry



Basic Components of Blood
Plasma Protein Separation Procedure
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Comparison of Recombinant Blood Products in China and Overseas
Blood Product Industry Chain
Time Length of Plasma Collection and Separation Process
Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs & Expenses
Production & Sales Cycle of Blood Products
Main Policies on China Blood Product Industry, 1989-2017
Development History of China Blood Product Industry
Comparison between China and the United States in Per Capita Consumption of Main Blood Products
Lot Release Volume of Major Blood Products in China, 2014-2019
Blood Product Structure in China (by Lot Release Volume), 2014-2019
Plasma Collection Policies in China vs. USA and European Countries
Per Capita Frequency of Plasma Donation and Plasma Collection Volume in China vs. Euro-America
Number of Plasma Collection Stations and YoY Growth Rate in China, 2008-2019
Plasma Station Approval of Major Blood Product Enterprises in China, 2014-2019
Plasma Collection Volume and YoY Growth Rate in China, 2008-2019
Comparison of Blood Products Listed in National Medical Insurance Catalogue: 2017vs2009
Plasma Supply and Demand in China, 2015-2025E
Comparison of Cap-lift Prices and Original Highest Retail Prices of Blood Products
Market Size of China Blood Product Industry, 2010-2019
Number of Plasma Stations and Plasma Volume of Major Blood Product Enterprises in China, As of Dec. 2019
Main Products of Major Blood Product Manufacturing Enterprises in China

- Revenue of Major Blood Product Enterprises in China, 2013-2019
- Net Income of Major Blood Product Enterprises in China, 2013-2019
- Revenue from Blood Products Business of Major Blood Product Enterprises in China, 2013-2019
- Market Share of China Blood Product Industry (by Enterprise), 2018
- Market Share of China Blood Product Industry (by Enterprise), 2019
- Lot Release Volume and YoY Growth Rate of Human Albumin in China, 2010-2019
- Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Albumin, 2019
- Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2019
- Market Share of Human Albumin in China (by Lot Release Volume), 2018
- Market Share of Human Albumin in China (by Lot Release Volume), 2019
- Lot Release Volume of Human Immunoglobulin for Intravenous Injection in China, 2010-2019
- Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin (pH4) for Intravenous Injection, 2019
- Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2018
- Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2019
- Comparison between China and the United States in Per Capita Consumption of Human Albumin and Human Immunoglobulin (pH4) for Intravenous Injection
- Lot Release Volume of Blood Coagulation Factor VIII in China, 2010-2019
- Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Coagulation Factor VIII, 2019
- Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2018
- Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2019
- Comparison between China and the United States in Per Capita Consumption of Coagulation Factor VIII
- Coagulation Factor VIII R&D Progress of Major Blood Product Enterprises in China, as of 2019H1
- Lot Release Volume of Hepatitis B Immunoglobulin in China, 2010-2019
- Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Hepatitis B Immunoglobulin, 2019

Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2018
Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2019
Lot Release Volume of Human Immunoglobulin in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin, 2019
Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2018
Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2019
Lot Release Volume of Human Prothrombin Complex in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Prothrombin Complex, 2019
Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2018
Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2019
Lot Release Volume of Tetanus Immunoglobulin in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Tetanus Immunoglobulin, 2019
Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2018
Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2019
Cases, Deaths and Mortality of Rabies in China, 2013-2019
Lot Release Volume of Human Rabies Immunoglobulin in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Rabies Immunoglobulin, 2019
Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2018
Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2019
Product Line of CBPO
Equity Structure of China Biologic Products Holdings
Revenue and Operating Income of CBPO, 2014-2019
Revenue Breakdown of CBPO (by Product), 2012-2019
Revenue Structure of CBPO (by Product), 2012-2019
Gross Margin of CBPO, 2012-2019

R&D Costs and % of Total Revenue of CBPO, 2012-2019

CBPO's Products under Research and R&D Process by the end of 2018

Main R&D Pipeline Products of Beijing TianXinFu Medical Appliance

Lot Release Volume of Blood Products of CBPO, 2016-2019

Main Plasma Collection Stations of Guizhou Taibang Biological Products as of Dec. 2019

Ownership Structure of Shandong Taibang Biological Products

Main Plasma Collection Stations of Shandong Taibang Biological Products as of Dec. 2019

Ownership Structure of Xi'an Huitian Blood Products

Main Plasma Collection Stations of Xi'an Huitian Blood Products as of Dec.2019

Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2017-2019

Revenue and Net Income of Hualan Biological Engineering, 2013-2019

Revenue Breakdown of Hualan Biological Engineering (by Product), 2013-2019

Revenue Structure of Hualan Biological Engineering (by Product), 2013-2019

Gross Margin of Blood Products of Hualan Biological Engineering (by Product), 2013-2019

R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2019

Category and Specification of Blood Products of Hualan Biological Engineering

Output, Sales Volume and Inventory of Blood Products of Hualan Biological Engineering, 2016-2018

Revenue of Blood Products of Hualan Biological Engineering, 2013-2019

Lot Release Volume of Blood Products of Hualan Biological Engineering, 2015-2019

Revenue and Net Income of Shanghai RAAS Blood Products, 2013-2019

Revenue Breakdown of Shanghai RAAS Blood Products (by Product), 2013-2019

Revenue Structure of Shanghai RAAS Blood Products (by Product), 2013-2019

Revenue Breakdown of Shanghai RAAS Blood Products (by Region), 2013-2019

Revenue Structure of Shanghai RAAS Blood Products (by Region), 2013-2019

Gross Margin of Shanghai RAAS Blood Products (by Product), 2013-2019



R&D Costs of Shanghai RAAS Blood Products, 2013-2019
Blood Products of Shanghai RAAS Blood Products and Its Subsidiaries
Output, Sales Volume and Inventory of Blood Products of Shanghai RAAS Blood Products, 2016-2018
Revenue and Net Income of Tiantan Biological Products, 2013-2019
Revenue Breakdown of TiantanBio (by Product), 2013-2019
Revenue Structure of TiantanBio (by Product), 2013-2019
Gross Margin of TiantanBio (by Product), 2013-2018
R&D Costs and % of Total Revenue of TiantanBio, 2013-2019
R&D Input of Major Projects of TiantanBio, 2018
Progress of Major R&D Projects of TiantanBio, by the End of 2018
TiantanBio's Major Blood Products Subsidiaries and Stake
Production and Sales of Main Blood Products of TiantanBio, 2018
Lot Release Volume of Main Blood Products of TiantanBio, 2015-2019
Revenue and Net Income of Chengdu Rongsheng Pharmaceutical, 2015-2019
Revenue and Net Income of Shuanglin Bio-Pharmacy, 2013-2019
Gross Margin of Shuanglin Bio-Pharmacy, 2013-2019
R&D Costs and % of Total Revenue of Guangdong Shuanglin Bio-Pharmacy, 2013-2019
Production-use Plasma Volume of Guangdong Shuanglin Bio-Pharmacy, 2013-2018
Production, Inventory and Sales of Main Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2013-2018
Lot Release Volume of Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2015-2019
Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2013-2019
Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2018
Revenue Structure of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2018
Revenue from Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
Revenue Proportion of Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018

Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Product), 2013-2018
Gross Margin of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2013-2018
R&D Costs of Jiangxi Boya Bio-Pharmaceutical, 2013-2019
Production and Sales of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2016-2018
Lot Release Volume of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2019
Revenue and Net Income of Shenzhen Weiguang Biological Products, 2014-2019
Revenue Breakdown of Shenzhen Weiguang Biological Products (by Product), 2014-2019
Revenue Structure of Shenzhen Weiguang Biological Products (by Product), 2014-2019
Gross Margin of Shenzhen Weiguang Biological Products, 2014-2019
Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2014-2019
R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2014-2019
Progress of Fundraising Projects of Shenzhen Weiguang Biological Products, as of 2019H1
Plasma Collection Volume of Shenzhen Weiguang Biological Products, 2014-2019
Production and Sales of Blood Products of Shenzhen Weiguang Biological Products, 2016-2018
Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2016-2018
Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2019H1
Lot Release Volume of Blood Products of Shenzhen Weiguang Biological Products, 2016-2019
Revenue and Net Income of Beijing Bohui Innovation Technology, 2014-2019
Revenue Breakdown of Beijing Bohui Innovation Technology by Product, 2014-2019
Revenue Structure of Beijing Bohui Innovation Technology by Product, 2014-2019
Gross Margin of Beijing Bohui Innovation Technology by Product, 2014-2019
R&D Costs and % of Total Revenue of Beijing Bohui Innovation Technology, 2014-2019
Progress of Major Blood Product R&D Projects of Beijing Bohui Innovation Technology, 2019H1
Major Blood Products of Beijing Bohui Innovation Technology
Financials of Beijing Bohui Innovation Technology, 2017-2019



Lot Release Volume of Blood Products of Hebei Da'an Pharmaceutical, 2016-2019
Lot Release Volume of Blood Products of Guangdong Weilun Biological Pharmaceutical, 2016-2019
Development Course of Zhongyuan Ruide Biological Products
Financial Data of Zhongyuan Ruide, 2014-2017
Plasmapheresis Centers of Wuhan ZhongyuanRuide Biological Products, as of Dec.2019
Lot Release Volume of Blood Products of Zhongyuan Ruide Biological Products, 2016-2019
Development History of Sichuan Yuanda Shuyang Pharmaceutical
Specification of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2016-2018
Plasma Collection Stations of Shanxi Kangbao Biological Product as of Dec. 2019
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2016-2019
Plasma Collection Stations of Green Cross China as of Jan. 2019
Lot Release Volume of Blood Products of Green Cross China, 2016-2019
Plasmapheresis Centers of Nanyue Biopharming, as of Dec.2019
Lot Release Volume of Blood Products of Nanyue Biopharming, 2016-2018
Market Size of Blood Products in China, 2018-2026E
M&A Cases of Foreign Blood Product Companies
M&A Cases in China Blood Product Industry, 2008-2019
Plasma Collection Volume and YoY Change in China, 2018-2026E
R&D Investment of Major Chinese Blood Product Enterprises, 2014-2019
Population Aged above 60 as a Percentage of Total Population in China, 2009-2018

You can place your order in the following alternative ways:

1. Order online at www.researchinchina.com
2. Fax order sheet to us at fax number: +86 10 82601570
3. Email your order to: report@researchinchina.com
4. Phone us at +86 10 82600828

Party A:			
Name:			
Address:			
Contact Person:		Tel	
E-mail:		Fax	

Party B:			
Name:	Beijing Waterwood Technologies Co., Ltd (ResearchInChina)		
Address:	Room 2-626, 6th Floor, No.1, Shanyuan Street, Haidian District, Beijing, 100080		
Contact Person:	Liao Yan	Phone:	86-10-82600828
E-mail:	report@researchinchina.com	Fax:	86-10-82601570
Bank details:	Beneficial Name: Beijing Waterwood Technologies Co., Ltd Bank Name: Bank of Communications, Beijing Branch Bank Address: NO.1 jinxiyuan shijicheng, Landianchang, Haidian District, Beijing Bank Account No #: 110060668012015061217 Routing No #: 332906 Bank SWIFT Code: COMMCNSHBJG		

Title	Format	Cost
<i>Total</i>		

Choose type of format

- PDF (Single user license)3,200 USD
- Hard copy 3,400 USD
- PDF (Enterprisewide license)..... 4,800 USD

※ Reports will be dispatched immediately once full payment has been received.
Payment may be made by wire transfer or credit card via PayPal.

About ResearchInChina

ResearchInChina (www.researchinchina.com) is a leading independent provider of China business intelligence. Our research is designed to meet the diverse planning and information needs of businesses, institutions, and professional investors worldwide. Our services are used in a variety of ways, including strategic planning, product and sales forecasting, risk and sensitivity management, and as investment research.

Our Major Activities

- *Multi-users market reports*
- *Database-RICDB*
- *Custom Research*
- *Company Search*

RICDB (<http://www.researchinchina.com/data/database.html>), is a visible financial data base presented by map and graph covering global and China macroeconomic data, industry data, and company data. It has included nearly 500,000 indices (based on time series), and is continuing to update and increase. The most significant feature of this base is that the vast majority of indices (about 400,000) can be displayed in map.

After purchase of our report, you will be automatically granted to enjoy 2 weeks trial service of RICDB for free.

After trial, you can decide to become our formal member or not. We will try our best to meet your demand. For more information, please find at www.researchinchina.com

For any problems, please contact our service team at: